Recurrences can occur in up to 30% of surgically managed patients with localized renal cell carcinoma. Existing uro-oncological guidelines differ in recommendations of surveillance protocols and identification of patients at risk. A recent study shows that the existence of differing guidelines results in inadequate harms, cancer control and costs.
展开▼